They just guided up 15% sequentially with 49% margins, but the street thinks it's an AI story when it's really a legacy capacity squeeze.
Thesis: This is a classic cyclical upswing masquerading as a technology pivot. The core ball bonder business is roaring back with utilization >80% globally and >90% in China. While the street argues over whether TCB survives HBM4, the legacy business is printing cash and driving the beat-and-raise cadence. You buy it for the cyclical recovery; the advanced packaging narrative is just the multiple expander.
Verdict: LONG — Conviction: MEDIUM
Catalyst: Q2 earnings where 15% sequential growth confirms the cycle turn, potentially forcing a guidance raise for full year FY26.
Key Risk: Hybrid bonding maturity accelerates, causing memory makers to skip TCB for HBM4, turning the $200M Singapore expansion into a stranded asset.
The Tell: The Gross Margin confession: 'Gross margins improved... due to revenue recognized from systems which were previously expensed.' The 49.6% print wasn't just pricing power; it was an accounting reversal from prior impairment charges. The operational margin is lower.
Friction Level: MODERATE_FRICTION — Durability of Thermocompression Bonding (TCB). Bulls see it as the HBM standard; Bears see it as a bridge to Hybrid Bonding that gets skipped.
Report not found
The report data is no longer available. Please return to the archive.